FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III

Freedom Broker analysts maintained their “Buy” rating on aTyr Pharma (ATYR) shares and a $3.50 price target. From the current price of $0.55, this implies upside potential of about 536%. Analysts believe the key near-term catalyst for a re-rating will be the FDA’s expected comments, due by the end of August, on the protocol for a new Phase III study of efzofitimod in pulmonary sarcoidosis.

A biotech company with one core asset

aTyr Pharma is an American clinical-stage biotechnology company developing therapies for inflammatory and fibrotic diseases. The company’s main asset is Efzofitimod, an experimental biologic being developed to treat interstitial lung diseases (ILD), including pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease.

Analysts believe that following constructive engagement with the U.S. Food and Drug Administration (FDA), uncertainty around the further development of Efzofitimod has decreased. At the same time, experts note that the investment case remains high-risk: the company still needs to conduct a new Phase III trial and raise additional funding.

FDA prepares the next step for Efzofitimod 

In June, aTyr Pharma submitted to the FDA the protocol for a planned international Phase III study in patients with chronic symptomatic pulmonary sarcoidosis and restrictive lung impairment. The company expects to receive the regulator’s comments by the end of August.

The planned study is expected to enroll about 372 patients. Participants will receive Efzofitimod at a dose of 5 mg/kg or placebo once every three weeks for 54 weeks. The primary endpoint will be the change in forced vital capacity (FVC) at 48 weeks.

Freedom Broker estimates that the study design could increase the likelihood of achieving a statistically significant result. The trial is expected to include only patients with a restrictive disease type, and background steroid therapy should remain stable. This, analysts believe, could reduce variability in treatment response.

Previously, the FDA agreed to allow more frequent dosing of Efzofitimod—once every three weeks instead of the once-every-four-weeks regimen used in the prior study. This schedule should provide a more stable blood concentration of the drug without increasing the single dose.

Restructuring extends the cash runway

At the same time, aTyr announced a large-scale restructuring. The company is cutting about 60% of its workforce. Management estimates that the restructuring and additional cost-cutting measures will reduce annual operating expenses by roughly $13 million starting in Q4 2026.

As of June 30, 2026, the company had $58.9 million in cash, cash equivalents, restricted cash, and investments. Management expects that, at the current spending level, these funds will be sufficient to finance operations through the end of 2028.

However, launching a new Phase III will require additional capital. The company may raise funds through an equity offering or debt financing, grants, partnerships, or licensing agreements. Potential shareholder dilution is cited by analysts as one of the key risks to the investment case.

Financial results reflect the development stage

aTyr does not yet have commercial revenue: the company is at the clinical stage of drug development. In Q2 2026, research and development expenses totaled $6.7 million. Selling, general and administrative expenses were $4.1 million.

New data could be the next driver

The company will conduct a new study of Efzofitimod  (EFZO-CONNECT) in patients with systemic sclerosis-associated interstitial lung disease. aTyr has already completed enrollment. Initial results are expected in Q1 2027.

Additional support for the investment thesis comes from an analysis of the previous Efzofitimod study. At the congress of the World Association of Sarcoidosis and Other Granulomatous Diseases, the company presented results in patients with a restrictive sarcoidosis phenotype, in whom Efzofitimod showed a clinically meaningful improvement in FVC (increased air volume) and a number of measures reflecting patients’ condition.

Freedom Broker emphasizes, however, that these results still need to be confirmed in a new controlled study. Therefore, analysts consider the most important near-term event to be the FDA’s response on the Phase III protocol at the end of August.

aTyr Pharma’s price target in the spring

Freedom Broker raised its price target for aTyr Pharma (ATYR) shares from $1 to $3.50 and upgraded its recommendation from “Hold” to “Buy.” The revision followed the FDA’s confirmation that Efzofitimod’s development could continue.

When the regulator agreed to the program’s further development and the parameters of the new Phase III study, Freedom Broker believes this significantly reduced the uncertainty that had persisted after the failure of the previous EFZO-FIT trial and increased the likelihood of successfully continuing the clinical program. At the same time, analysts maintain caveats related to clinical risks and the need for additional funding.

Not an individual investment recommendation.